Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Therapy
  4. Fast Track Articles
  5. Fast Track Article
image of Lipid-lowering Effect of Coriolus versicolor Extract in Statin-intolerant Patients with Hypercholesterolemia

Abstract

Introduction

Hypercholesterolemia is one of the main risk factors for cardiovascular diseases and atherosclerosis, which remain the most widespread disease burden worldwide. Statins are the standard procedure for regulating lipid levels, which are recommended as the first medical step to reduce cardiovascular risk; however, many patients present adverse muscle reactions to the treatment. When statin intolerance occurs, other therapies need to be implemented as supportive or substitutive means.

Case presentation

A woman with primary hypercholesterolemia and statin intolerance due to myopathy and headache was treated with 30mg/kg/day of (CV) mushroom extract combined with regular aerobic physical activity and a healthy diet. After 30 days of therapy, the reduction in all lipid profile parameters exceeded 11%. The atherogenic index of plasma AIP decreased from 0.55 to 0.48. Additionally, no adverse reactions to therapy were observed.

Conclusion

Results confirmed the potential of natural products of CV extract in reducing hypercholesterolemia in patients who are intolerant to statins.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdth/10.2174/0115748855367644250226113829
2025-03-07
2025-06-17

  • From This Site

    /content/journals/cdth/10.2174/0115748855367644250226113829
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. World health statistics 2023: Monitoring health for the SDGs, sustainable development goals. 2023 Available from: https://www.who.int/publications/i/item/9789240074323
  2. Pirillo A. Norata G.D. The burden of hypercholesterolemia and ischemic heart disease in an ageing world. Pharmacol. Res. 2023 193 106814 10.1016/j.phrs.2023.106814 37271426
    [Google Scholar]
  3. Mach F. Baigent C. Catapano A.L. Koskinas K.C. Casula M. Badimon L. Chapman M.J. De Backer G.G. Delgado V. Ference B.A. Graham I.M. Halliday A. Landmesser U. Mihaylova B. Pedersen T.R. Riccardi G. Richter D.J. Sabatine M.S. Taskinen M.R. Tokgozoglu L. Wiklund O. Mueller C. Drexel H. Aboyans V. Corsini A. Doehner W. Farnier M. Gigante B. Kayikcioglu M. Krstacic G. Lambrinou E. Lewis B.S. Masip J. Moulin P. Petersen S. Petronio A.S. Piepoli M.F. Pintó X. Räber L. Ray K.K. Reiner Ž. Riesen W.F. Roffi M. Schmid J-P. Shlyakhto E. Simpson I.A. Stroes E. Sudano I. Tselepis A.D. Viigimaa M. Vindis C. Vonbank A. Vrablik M. Vrsalovic M. Zamorano J.L. Collet J-P. Koskinas K.C. Casula M. Badimon L. John Chapman M. De Backer G.G. Delgado V. Ference B.A. Graham I.M. Halliday A. Landmesser U. Mihaylova B. Pedersen T.R. Riccardi G. Richter D.J. Sabatine M.S. Taskinen M-R. Tokgozoglu L. Wiklund O. Windecker S. Aboyans V. Baigent C. Collet J-P. Dean V. Delgado V. Fitzsimons D. Gale C.P. Grobbee D. Halvorsen S. Hindricks G. Iung B. Jüni P. Katus H.A. Landmesser U. Leclercq C. Lettino M. Lewis B.S. Merkely B. Mueller C. Petersen S. Petronio A.S. Richter D.J. Roffi M. Shlyakhto E. Simpson I.A. Sousa-Uva M. Touyz R.M. Nibouche D. Zelveian P.H. Siostrzonek P. Najafov R. van de Borne P. Pojskic B. Postadzhiyan A. Kypris L. Špinar J. Larsen M.L. Eldin H.S. Viigimaa M. Strandberg T.E. Ferrières J. Agladze R. Laufs U. Rallidis L. Bajnok L. Gudjónsson T. Maher V. Henkin Y. Gulizia M.M. Mussagaliyeva A. Bajraktari G. Kerimkulova A. Latkovskis G. Hamoui O. Slapikas R. Visser L. Dingli P. Ivanov V. Boskovic A. Nazzi M. Visseren F. Mitevska I. Retterstøl K. Jankowski P. Fontes-Carvalho R. Gaita D. Ezhov M. Foscoli M. Giga V. Pella D. Fras Z. de Isla L.P. Hagström E. Lehmann R. Abid L. Ozdogan O. Mitchenko O. Patel R.S. ESC Scientific Document Group 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. 2020 41 1 111 188 10.1093/eurheartj/ehz455 31504418
    [Google Scholar]
  4. Kosmas C.E. Rodriguez Polanco S. Bousvarou M.D. Papakonstantinou E.J. Peña Genao E. Guzman E. Kostara C.E. The triglyceride/high-density lipoprotein cholesterol (TG/HDL-C) ratio as a risk marker for metabolic syndrome and cardiovascular disease. Diagnostics 2023 13 5 929 10.3390/diagnostics13050929 36900073
    [Google Scholar]
  5. Niroumand S. Khajedaluee M. Khadem-Rezaiyan M. Abrishami M. Juya M. Khodaee G. Dadgarmoghaddam M. Atherogenic index of plasma (AIP): A marker of cardiovascular disease. Med. J. Islam. Repub. Iran 2015 29 240 26793631
    [Google Scholar]
  6. Ramkumar S. Raghunath A. Raghunath S. Statin therapy: Review of safety and potential side effects. Zhonghua Minguo Xinzangxue Hui Zazhi 2016 32 6 631 639 27899849
    [Google Scholar]
  7. Khan A. Maki K.C. Ito M.K. Cohen J.D. Sponseller C.A. Bell M. Brinton E.A. Jacobson T.A. Statin associated muscle symptoms: Characteristics of patients and recommendations by providers. J. Clin. Lipidol. 2015 9 3 460 10.1016/j.jacl.2015.03.080
    [Google Scholar]
  8. Al Shohaib S. Simvastatin-induced rhabdomyolysis in a patient with chronic renal failure. Am. J. Nephrol. 2000 20 3 212 213 10.1159/000013589 10878403
    [Google Scholar]
  9. Golomb B.A. Evans M.A. Statin adverse effects : A review of the literature and evidence for a mitochondrial mechanism. Am. J. Cardiovasc. Drugs 2008 8 6 373 418 10.2165/0129784‑200808060‑00004 19159124
    [Google Scholar]
  10. Nikolic M. Lazarevic N. Novakovic J. Jeremic N. Jakovljevic V. Zivkovic V. Bradic J. Pecarski D. Tel-Çayan G. Glamocija J. Sokovic M. Gregori A. Petrovic J. Characterization, in vitro biological activity and in vivo cardioprotective properties of Trametes versicolor (L.:Fr.) Quél. heteropolysaccharides in rat model of metabolic syndrome. Pharmaceuticals 2023 16 6 787 10.3390/ph16060787 37375735
    [Google Scholar]
  11. Jędrzejewski T. Pawlikowska M. Sobocińska J. Wrotek S. COVID-19 and cancer diseases - The potential of Coriolus versicolor mushroom to combat global health challenges. Int. J. Mol. Sci. 2023 24 5 4864 10.3390/ijms24054864 36902290
    [Google Scholar]
  12. Srivastava M. Kumari M. Karn S.K. Bhambri A. Mahale V.G. Mahale S. Submerged cultivation and phytochemical analysis of medicinal mushrooms (Trametes sp.). Front. Fungal Biol. 2024 5 1414349 10.3389/ffunb.2024.1414349 38919599
    [Google Scholar]
  13. Wasser S. Medicinal mushroom science: Current perspectives, advances, evidences, and challenges. Biomed. J. 2014 37 6 345 356 10.4103/2319‑4170.138318 25179726
    [Google Scholar]
  14. Lowenthal R. Taylor M. Gidden J.A. Heflin B. Lay J.O. Jr Avaritt N. Tackett A.J. Urbaniak A. The mycelium of the Trametes versicolor synn. Coriolus versicolor (Turkey tail mushroom) exhibit anti-melanoma activity in vitro. Biomed. Pharmacother. 2023 161 114424 10.1016/j.biopha.2023.114424 36827712
    [Google Scholar]
  15. Habtemariam S. Trametes versicolor (Synn. Coriolus versicolor) polysaccharides in cancer therapy: Targets and efficacy. Biomedicines 2020 8 5 135 10.3390/biomedicines8050135 32466253
    [Google Scholar]
  16. Hor S.Y. Farsi E. Yam M.F. Lipid-lowering effects of Coriolus versicolor extract in poloxamer 407-induced hypercholesterolaemic rats and high cholesterol-fed rats. J. Med. Plants Res. 2011 5 11 2261 2266
    [Google Scholar]
  17. Wu Q. Wang Q. Fu J. Ren R. Polysaccharides derived from natural sources regulate triglyceride and cholesterol metabolism: A review of the mechanisms. Food Funct. 2019 10 5 2330 2339 10.1039/C8FO02375A 31049523
    [Google Scholar]
  18. Wong C.K. Tse P.S. Wong E.L.Y. Leung P.C. Fung K.P. Lam C.W.K. Immunomodulatory effects of Yun Zhi and Danshen capsules in health subjects—a randomized, double-blind, placebo-controlled, crossover study. Int. Immunopharmacol. 2004 4 2 201 211 10.1016/j.intimp.2003.12.003 14996412
    [Google Scholar]
  19. Chu K.K.W. Ho S.S.S. Chow A.H.L. Coriolus versicolor: A medicinal mushroom with promising immunotherapeutic values. J. Clin. Pharmacol. 2002 42 9 976 984 10.1177/009127000204200904 12211223
    [Google Scholar]
  20. Meng F. Lin Y. Hu L. Feng W. Su P. Wu L. The therapeutic effect of Corolius Versicolor fruiting body on STZ-Induced ICR diabetic mice. J. Healthc. Eng. 2022 2022 1 9 10.1155/2022/7282453 35463673
    [Google Scholar]
  21. Huang Z. Zhang M. Wang Y. Zhang S. Jiang X. Extracellular and intracellular polysaccharide extracts of Trametes Versicolor improve lipid profiles via serum regulation of lipid-regulating enzymes in hyperlipidemic mice. Curr. Microbiol. 2020 77 11 3526 3537 10.1007/s00284‑020‑02156‑3 32780205
    [Google Scholar]
/content/journals/cdth/10.2174/0115748855367644250226113829
Loading
Lipid-lowering Effect of Coriolus versicolor Extract in Statin-intolerant Patients with Hypercholesterolemia
Bentham Science Publishers ; https://doi.org/10.2174/0115748855367644250226113829
/content/journals/cdth/10.2174/0115748855367644250226113829
/content/journals/cdth/10.2174/0115748855367644250226113829
Loading

Data & Media loading...


  • Article Type:     Case Report
Keywords: turkey tail ; statin intolerance ; Coriolus versicolor ; therapy ; Hypercholesterolemia ; cardiovascular risk

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test